Applied Labs
Executive Summary
ANDA for acetaminophen/hydrocodone combo denied on basis that hydrocodone component would eliminate ability to titrate a patient to the lowest effective dose of narcotic consistent with approved indications. FDA also objected to "severe pain" indication. FDA noted that "no hydrocodone bitartrate product, alone or in combination has been approved for that indication".